Tislelizumab + Fruquintinib

Phase 2Recruiting

1 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Minimal Residual Disease

Conditions

Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer, Fruquintinib, Tislelizumab, ctDNA

Trial Timeline

Sep 18, 2025 → Apr 1, 2028

NCT ID

NCT07136077

About Tislelizumab + Fruquintinib

Tislelizumab + Fruquintinib is a phase 2 stage product being developed by Takeda Pharmaceutical for Minimal Residual Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07136077. Target conditions include Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07136077	Phase 2	Recruiting	Sep 18, 2025	Apr 1, 2028	Minimal Residual Disease

Competing Products

4 competing products in Minimal Residual Disease

See all competitors

Product	Company	Stage	Hype Score
Pudexacianinium chloride	Astellas Pharma	Phase 2	35
Blinatumomab in combination with donor lymphocyte infusion	Amgen	Phase 2	27
Clofarabine + Cytarabine intravenous + Methotrexate + Intrathecal (IT) Cytarabine	Sanofi	Phase 2	27
Rifaximin + rifaximin	Bausch Health	Phase 1/2	26